Pulmonary Hypertension

January 19, 2018January 19, 2018

Eiger BioPharmaceuticals Discontinues Development of Ubenimex in PAH After Disappointing Results

Eiger BioPharmaceuticals will discontinue the development of ubenimex as a therapy for pulmonary arterial hypertension (PAH) due to disappointing results in the Phase 2 LIBERTY clinical trial. The treatment failed to ... Read more

January 11, 2018January 11, 2018

Bellerophon Enrolls First Patient in Study of INOpulse to Treat PH Linked to Interstitial Lung Disease

Idiopathic Pulmonary Fibrosis, News, Pulmonary Hypertension

A Phase 2b clinical study evaluating INOpulse as a treatment for pulmonary hypertension (PH) associated with interstitial lung disease (PH-ILD) enrolled the first patient, Bellerophon Therapeutics has announced. Patients with ... Read more

November 15, 2017November 15, 2017

Canadian Association Conducting Purple Challenge Campaign During PH Awareness Month

News, Pulmonary Hypertension

The Pulmonary Hypertension Association of Canada is conducting a Life in Purple Challenge this month as part of its efforts to mark November as Pulmonary Hypertension Awareness Month. The goal is to raise ... Read more

September 5, 2017September 5, 2017

SteadyMed’s NDA for Trevyent to Treat PAH Refused by FDA; More Information Needed

Pulmonary Hypertension

The U.S. Food and Drug Administration rejected SteadyMed’s new drug application (NDA) for Trevyent (treprostinil), a treatment for pulmonary arterial hypertension (PAH). According to the FDA’s Refusal to File letter, the ... Read more

July 25, 2017July 25, 2017

ZappRx Implements Specialty Medication Prescribing Platform at 2 Pulmonary Medical Centers

Cystic Fibrosis, Idiopathic Pulmonary Fibrosis, News, Pulmonary Hypertension

Harbor-UCLA Medical Center in Torrance, California, and Phoenix-based Arizona Pulmonary Specialists — the largest U.S. private practice treating pulmonary hypertension — now offer a digital platform designed by ZappRx to facilitate the complex ... Read more

July 18, 2017July 18, 2017

Mount Sinai, Theragene Collaborate to Develop New Gene Therapy for Pulmonary Hypertension

News, Pulmonary Hypertension

Researchers from New York’s Mount Sinai have partnered with Theragene Pharmaceuticals to further develop a new airway-delivered gene therapy for pulmonary hypertension (PH). After showing promising results in animal studies, this new therapy will advance to clinical trials, ... Read more

June 1, 2017June 1, 2017

Lung Stem Cells Offer Biomarkers for Earlier Lung Disease Diagnosis

Idiopathic Pulmonary Fibrosis, News, Pulmonary Hypertension

The characterization of a type of pulmonary stem cells in adult lung tissue might lead to earlier diagnoses of chronic lung diseases, as researchers have identified factors in the cells ... Read more

May 24, 2017June 19, 2017

INOpulse Nitric Oxide System Seen to Treat PH Patients with IPF and COPD Symptoms

COPD, Idiopathic Pulmonary Fibrosis, News, Pulmonary Hypertension

The INOpulse nitric oxide delivery system met its primary Phase 2 clinical trial goal of increasing the blood-vessel volume of pulmonary hypertension patients with idiopathic pulmonary fibrosis (PH-IPF), according to its maker, Bellerophon Therapeutics. ... Read more

May 2, 2017May 2, 2017

Bellerophon’s INOpulse Shows Promising Results in Patients with PH-IPF Lung Disease

Idiopathic Pulmonary Fibrosis, News, Pulmonary Hypertension

Inhaled nitric oxide (iNO) treatment with the investigational medical device INOpulse system in patients with pulmonary hypertension associated with idiopathic pulmonary fibrosis (PH-IPF) has shown promising results in a Phase 2 clinical ... Read more

February 15, 2017February 15, 2017

EMA Reviewing Safety of Uptravi After 5 Deaths Reported in PAH Patients in France

News, Pulmonary Hypertension

The European Medicines Agency (EMA) is re-examining the safety of Uptravi (selexipag) after five pulmonary arterial hypertension (PAH) patients in France died while taking the medicine, the agency announced in a ... Read more